PP01.44 Long-Term Survival and Outcomes by Race from the Phase I/II trial of Carboplatin, Nab-paclitaxel, and Pembrolizumab for Advanced NSCLC: HCRN LUN13-175

Combination chemotherapy and immunotherapy regimens have significantly improved survival for patients with previously untreated advanced non-small cell lung cancer (NSCLC). In phase III trials combining chemotherapy and immunotherapy, 3-year OS has been reported at 30% (Keynote 407), 31% (Keynote 189), and 27% (Checkmate 9LA). We conducted a phase I/II trial of pembrolizumab with nab-paclitaxel and carboplatin in all-histology NSCLC. Previous FDA-approved phase III trials using chemotherapy and immunotherapy combinations enrolled only 1% Black/African American patients. Here we report long-term outcomes and outcomes by race.